Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29344497 | 0.87 | CYP4F2 (0.34) | KRASCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL24779651 | 0.81 | CYP4F2 (0.41) | KRASCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL29563167 | 0.80 | CYP4F2 (0.40) | KRASCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL24460667 | 0.80 | CYP4F2 (0.40) | KRASCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL30932779 | 0.79 | RXRA (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29937341 | 0.77 | CYP4F2 (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL21196104 | 0.74 | CYP4F2 (0.42) | KRASCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL29563445 | 0.74 | CYP4F2 (0.42) | KRASCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL21196042 | 0.74 | CYP4F2 (0.47) | KRASCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL23546397 | 0.73 | CYP4F2 (0.43) | KRASCYP4F2CYP4A11RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151004-A1 | PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | D3 BIO (WUXI) CO., LTD (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230151004-A1 | PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | D3 BIO (WUXI) CO., LTD (CN) | 2023-05-18 | — | — | US | disclosed |
| EP-4105211-A1 | PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | D3 Bio(Wuxi) Co., Ltd. (CN) | 2022-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151004-A1 | PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF | TYMP, DHFR, DPYD | KRAS 435/4885CYP4F2 121/4885CYP4A11 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.